AAN

New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...

New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment ...

The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...

Prof. Michael Levy highlights the first positive phase 3 trial in MOGAD and what it could mean for future standards of care. Relapse prevention remains one of the greatest unmet needs in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where recurrent inflammatory ...

New data shaping diagnosis, treatment strategies and long-term management in epilepsy The American Epilepsy Society Annual Meeting 2025 brought together leading experts to showcase the latest developments in epilepsy research and clinical care. The meeting highlighted significant progress in Dravet Syndrome, ...

Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...

Nominated as a touchNEUROLOGY Future Leader 2025, we met with Dr Antonella Macerollo, Consultant Neurologist at The Walton Centre NHS Foundation Trust and Honorary Clinical Associate Professor at the University of Liverpool, UK. With a specialist focus on movement disorders and advanced neuromodulation therapies such as deep brain stimulation (DBS) and MRI-guided focused ultrasound, Dr Macerollo shares her personal journey into neurology, the mentors who shaped her path, and her vision for more equitable, personalized neurological care.

touchNEUROLOGY is delighted to congratulate Dr Amit Bar-Or of Penn Medicine on receiving the 2025 John Dystel Prize for Multiple Sclerosis Research, jointly awarded by the National Multiple Sclerosis Society (NMMS) and the American Academy of Neurology (AAN). This honour recognizes his groundbreaking work in neuroimmunology, precision medicine, and biomarker research in multiple sclerosis (MS).

The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.